Perrigo Company PLC (PRGO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Perrigo Company PLC stock (PRGO) is currently trading at $9.69. Perrigo Company PLC PS ratio (Price-to-Sales) is 0.30. Analyst consensus price target for PRGO is $17.00. WallStSmart rates PRGO as Underperform.
- PRGO PE ratio analysis and historical PE chart
- PRGO PS ratio (Price-to-Sales) history and trend
- PRGO intrinsic value — DCF, Graham Number, EPV models
- PRGO stock price prediction 2025 2026 2027 2028 2029 2030
- PRGO fair value vs current price
- PRGO insider transactions and insider buying
- Is PRGO undervalued or overvalued?
- Perrigo Company PLC financial analysis — revenue, earnings, cash flow
- PRGO Piotroski F-Score and Altman Z-Score
- PRGO analyst price target and Smart Rating
Perrigo Company
📊 No data available
Try selecting a different time range
Smart Analysis
Perrigo Company PLC (PRGO) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in peg ratio, price/sales, price/book. Concerns around return on equity and revenue growth. Mixed signals suggest waiting for clearer direction before acting.
Perrigo Company PLC (PRGO) Key Strengths (4)
Paying less than $1 for every $1 of annual revenue
Trading below book value, meaning the market prices it less than net assets
115.66% of shares held by major funds and institutions
Good growth relative to its price
Supporting Valuation Data
Perrigo Company PLC (PRGO) Areas to Watch (6)
Company is destroying shareholder value
Revenue declining -2.50%, a shrinking business
Earnings declining -63.60%, profits shrinking
Company is losing money with a negative profit margin
Thin operating margins with cost pressures present
Small-cap company with higher risk but more growth potential
Perrigo Company PLC (PRGO) Detailed Analysis Report
Overall Assessment
This company scores 48/100 in our Smart Analysis, earning a D+ grade. Out of 10 metrics analyzed, 4 register as strengths (avg 9.5/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book, Institutional Own.. Valuation metrics including PEG Ratio (1.14), Price/Sales (0.30), Price/Book (0.43) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, EPS Growth. Growth concerns include Revenue Growth at -2.50%, EPS Growth at -63.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -38.70%, Operating Margin at 10.20%, Profit Margin at -33.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -38.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -2.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
PRGO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
PRGO's Price-to-Sales ratio of 0.30x trades at a deep discount to its historical average of 2.65x (0th percentile). The current valuation is 95% below its historical high of 6.44x set in Apr 2015, and 0% above its historical low of 0.3x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~0.4x as trailing revenue scaled faster than the stock price.
Compare PRGO with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Perrigo Company PLC (PRGO) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Perrigo Company PLC is in a turnaround phase, with management focused on restoring profitability. Revenue reached 4.3B with 3% decline year-over-year. The company is currently unprofitable, posting a -33.5% profit margin.
Key Findings
Generating 149M in free cash flow and 175M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -33.5% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Dividend sustainability with a current yield of 12.0%. Watch payout ratio and free cash flow coverage.
Debt management: total debt of 3.8B is significantly higher than cash (432M). Monitor refinancing risk.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Perrigo Company PLC.
Bottom Line
Perrigo Company PLC is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Perrigo Company PLC(PRGO)
NYSE
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Perrigo Company plc is an American Irish registered manufacturer of private label over-the-counter pharmaceuticals.